Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Shanghai Generon Initiates a Phase II Trial for Breast Cancer in the US

publication date: May 9, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Shanghai Generon announced that it will initiate a randomized, multi-center Phase 2 clinical trial in the US in breast cancer patients receiving myelotoxic chemotherapy. The company believes F-627 is one of the first innovative biologic drug candidates developed by a Chinese biotech company to enter global clinical development. More details…

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...